Drug Profile


Alternative Names: BAM-002; Cisplatin/glutathione; Glutathione/cisplatin - Novelos Therapeutics; Glutoxim; NOV-002

Latest Information Update: 02 Apr 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BAM
  • Developer BAM; Cellectar Biosciences; Novelos Therapeutics
  • Class Oligopeptides; Platinum complexes
  • Mechanism of Action Immunomodulators; Protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Cancer
  • Suspended Breast cancer; Ovarian cancer; Radiation injuries
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 11 Feb 2014 Novelos Therapeutics is now called Cellectar Biosciences
  • 11 Apr 2011 Suspended - Phase-II for Breast cancer in USA (Parenteral)
  • 11 Apr 2011 Suspended - Phase-II for Ovarian cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top